Drug Trial Radar · NCT05770219
Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Approved for marketing
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 15, 2023
Design
- Study type
- Expanded access
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The expanded access program allows people to gain access to unlicensed treatment on compassionate grounds. TAK-755 also known as rADAMTS13, is a medicine that treats people born with severe congenital or hereditary thrombotic thrombocytopenic purpura (cTTP). This expanded access program enables continued access to those participants who have no other treatment options available for cTTP.
Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755Drug
TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.